JP2023548310A5 - - Google Patents
Info
- Publication number
- JP2023548310A5 JP2023548310A5 JP2023526266A JP2023526266A JP2023548310A5 JP 2023548310 A5 JP2023548310 A5 JP 2023548310A5 JP 2023526266 A JP2023526266 A JP 2023526266A JP 2023526266 A JP2023526266 A JP 2023526266A JP 2023548310 A5 JP2023548310 A5 JP 2023548310A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- pharmaceutical product
- product according
- moiety
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108020P | 2020-10-30 | 2020-10-30 | |
| US63/108,020 | 2020-10-30 | ||
| US202163197926P | 2021-06-07 | 2021-06-07 | |
| US63/197,926 | 2021-06-07 | ||
| PCT/US2021/057330 WO2022094262A1 (en) | 2020-10-30 | 2021-10-29 | Fap-activated serum extended half-life therapeutic conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548310A JP2023548310A (ja) | 2023-11-16 |
| JP2023548310A5 true JP2023548310A5 (https=) | 2024-09-20 |
Family
ID=78819635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526266A Pending JP2023548310A (ja) | 2020-10-30 | 2021-10-29 | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230390409A1 (https=) |
| EP (1) | EP4237012A1 (https=) |
| JP (1) | JP2023548310A (https=) |
| KR (1) | KR20230141754A (https=) |
| TW (1) | TW202227139A (https=) |
| WO (1) | WO2022094262A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| US20230381330A1 (en) * | 2020-10-30 | 2023-11-30 | Avacta Life Sciences Limited | Enzyme-activated serum extended half-life therapeutic conjugates |
| AU2023303082A1 (en) * | 2022-07-05 | 2025-01-23 | Alex Zounek | Prodrug kit for multi-pronged chemotherapy |
| WO2026002995A1 (en) | 2024-06-24 | 2026-01-02 | Avacta Life Sciences Limited | Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| HRP20120895T1 (hr) | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| RU2636046C2 (ru) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| US8828678B2 (en) | 2010-11-16 | 2014-09-09 | Enzo Life Sciences, Inc. | Self-immolative probes for enzyme activity detection |
| US9089614B2 (en) | 2012-12-21 | 2015-07-28 | Bioalliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| CN106456799B (zh) * | 2014-06-03 | 2020-05-22 | 江苏佳瑞生物技术有限公司 | 肽-药物偶联物 |
| CN106573073B (zh) * | 2014-06-13 | 2021-09-28 | 塔夫茨大学信托人 | Fap激活的治疗剂以及其相关用途 |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| US20210353652A1 (en) | 2018-06-04 | 2021-11-18 | Trustees Of Tufts College | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
-
2021
- 2021-10-29 JP JP2023526266A patent/JP2023548310A/ja active Pending
- 2021-10-29 US US18/034,225 patent/US20230390409A1/en active Pending
- 2021-10-29 KR KR1020237017996A patent/KR20230141754A/ko active Pending
- 2021-10-29 WO PCT/US2021/057330 patent/WO2022094262A1/en not_active Ceased
- 2021-10-29 EP EP21816231.1A patent/EP4237012A1/en active Pending
- 2021-11-01 TW TW110140602A patent/TW202227139A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548310A5 (https=) | ||
| Yadav et al. | Advances in delivery of chemotherapeutic agents for cancer treatment | |
| Peng et al. | Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer | |
| JP2025066807A (ja) | 生体直交型組成物 | |
| Larson et al. | Polymeric conjugates for drug delivery | |
| Hamman et al. | Oral delivery of peptide drugs: barriers and developments | |
| Ding et al. | HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug | |
| Davoodi et al. | Internalizing RGD, a great motif for targeted peptide and protein delivery: a review article | |
| ES2711669A1 (es) | Sistemas de liberacion de farmacos de acido polisialico y metodos | |
| JP2023548136A5 (https=) | ||
| Sorolla et al. | Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment | |
| US8889828B2 (en) | Conformations of divergent peptides with mineral binding affinity | |
| Li et al. | Recent advances in peptide-based therapeutic strategies for breast cancer treatment | |
| JP2023548310A (ja) | Ｆａｐ活性化血清半減期延長型治療用コンジュゲート | |
| Peng et al. | Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy | |
| Ruoslahti | Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier | |
| Lee et al. | Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy | |
| Wu et al. | Inflammation-targeted drug delivery strategies via albumin-based systems | |
| Jeswani et al. | Recent advances in the delivery of chemotherapeutic agents | |
| WO2011005098A1 (en) | Peptide ligands for targeting to the blood-brain barrier | |
| JP2020527556A5 (https=) | ||
| JP7837558B2 (ja) | 活性剤を送達する生体適合ポリマー薬物担体 | |
| Zhao et al. | Nanomaterials for acute myeloid leukemia therapy: current progress and future perspectives | |
| Basak et al. | Fibroblast activation protein as a molecular handle in cancer phototheranostics: recent advances | |
| EP4682156A1 (en) | Linker and drug conjugate using same, and antibody-drug conjugate and use thereof |